ADC Therapeutics (ADCT) Total Current Liabilities (2019 - 2026)

ADC Therapeutics (ADCT) has reported Total Current Liabilities for 8 consecutive years, with $67.6 million the latest figure, recorded in Q1 2026.

• Quarterly Total Current Liabilities rose 17.02% year-over-year to $67.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $67.6 million (up 17.02% YoY) and the FY2025 annual result came in at $70.2 million, down 12.81% from the prior year.
• Total Current Liabilities declined to $67.6 million in Q1 2026 per ADCT's latest filing, from $70.2 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ADCT reached as high as $87.6 million in Q3 2022 and fell as low as $57.6 million in Q2 2024.
• A 5-year average of $71.3 million and a median of $70.2 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities soared 70.96% — and 2024, when it dropped 28.48%.
• Year by year, Total Current Liabilities stood at $81.9 million in 2022, then dropped by 17.41% to $67.7 million in 2023, then rose by 18.91% to $80.5 million in 2024, then fell by 12.81% to $70.2 million in 2025, then fell by 3.61% to $67.6 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $67.6 million, $70.2 million, and $62.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.